Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone 5 mg vs 10 mg for Uterine Leiomyomata
NCT00886873Phase 3Completed
- Sponsor
- Mediterranea Medica
- Start
- May 2008
- Primary completion
- Apr 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mifepristone in uterine leiomyoma (2 arms), sponsored by Mediterranea Medica. Primary endpoint: Volume of the uterine leiomyomata at 6 months. Started May 2008; status: completed.
02
Drugs
mifepristone
03
Conditions
uterine leiomyoma
Beyond the preview
Go deeper on NCT00886873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886873.